-
Reduce cough frequency by 34%, innovative P2X3 receptor antagonist Phase 2 clinical results are positive
Time of Update: 2021-12-29
On December 13, 2021, Bellus Health announced that a phase 2b clinical trial of the selective oral P2X3 receptor antagonist BLU-5937 has obtained positive results .
-
Bayer's P2X3 receptor antagonist eliapixant in the treatment of RCC phase 2 clinical reached the efficacy endpoint
Time of Update: 2021-08-14
This is an international, placebo-controlled, randomized, double-blind, parallel group, dose discovery study to evaluate the treatment refractory of the oral potent and selective P2X3 receptor antagonist eliapixant (BAY1817080) compared with placebo Efficacy and safety of patients with chronic cough (RCC) .
-
Am J Gastr: Proton pump inhibitors and histamine 2 receptor antagonists have no special effects on the risk of gastric cancer
Time of Update: 2021-06-10
This study aimed to evaluate the association between the use of PPI and histamine 2 receptor antagonist (H2RA) and the risk of gastric cancer.
This study confirmed that even in high-risk areas of gastric cancer, long-term use of PPI and H2RA treatment did not show a higher risk of gastric cancer.
-
Oral GnRH receptor antagonists for endometriosis Phase 2 Clinical End.
Time of Update: 2020-07-20
On June 23, Myovant Sciences published the top-line results of the SPIRIT 1 study, the second phase III study to evaluate the relugolix combination therapy (relugolix 40mg plus estradiol 1.0mg plus ac
-
The first nasal administration up to 2/3 of the main endpoint CGRP receptor antagonists can quickly relieve migraines
Time of Update: 2020-05-31
Migraines are the most common cause of severe headaches in the world People who experience frequent migraines may lose more than half of their normal lives as a result of migraines The disease robs pa
-
Brit J Cancer: Proton pump inhibitors and histamine-2 receptor antagonists and stomach cancer risk
Time of Update: 2020-05-29
Studies have shown that the risk of stomach cancer increases in users of proton pump inhibitors (PPI) and histamine 2 receptor antagonists, and therefore the safety of gastric acid suppression is q
-
Research status of H 2 receptor antagonist lafutidine
Time of Update: 2016-11-22
There are two main methods for the synthesis of lafutidine: using 2-amino-4-methylpyridine as the starting material, first halogenating, amino being replaced by halogen, then oxidizing, methyl being o
